Trial Profile
A Multi-enter, Randomized, Double-blind, Placebo-controlled, Four-way Incomplete Block Crossover Study to Examine Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Single and Repeat Administration of Three Inhaled Doses (10, 15, and 20 Mcg) of GSK159797
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Milveterol (Primary) ; Salmeterol
- Indications Asthma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 13 Oct 2008 Trial centre added and phase ammended as reported by ClinicalTrials.gov.
- 02 Apr 2007 Status changed from recruiting to completed.
- 04 Nov 2006 New trial record.